Hormone Therapy for Prostate Cancer
Hormone therapy for prostate cancer usually means androgen deprivation therapy (ADT) and related medicines that reduce or block the effect of male hormones, particularly testosterone. Prostate cancer cells commonly depend on androgen signalling to grow. ADT is the foundation of treatment for metastatic prostate cancer and is often combined with additional androgen-receptor pathway treatment. It is also used for a defined period with radiation therapy in selected intermediate- and high-risk localized cancers. ADT can control cancer very effectively, but it affects the whole body: hot flushes, loss of libido, erectile dysfunction, muscle loss, fat gain, bone thinning and metabolic changes are important parts of treatment planning.
How does ADT lower testosterone?
| Method | How it works | Practical point |
|---|---|---|
| GnRH agonist injection | Initially stimulates, then suppresses pituitary signalling to the testes | Can cause a short testosterone “flare” at the start; flare protection may be used when clinically important. |
| GnRH antagonist injection or tablet | Directly blocks GnRH signalling and lowers testosterone rapidly | Avoids testosterone flare and may be useful when rapid suppression is needed. |
| Bilateral orchiectomy | Surgically removes the main source of testicular testosterone | One-time, permanent and rapidly effective; used less often but remains a valid option. |
What are androgen-receptor pathway inhibitors?
These medicines block androgen production or androgen-receptor signalling more completely than traditional ADT alone. In metastatic hormone-sensitive prostate cancer, combining one of these agents with ADT improves outcomes for many patients. They are also used in several castration-resistant settings. Choice depends on disease state, previous therapy, cardiovascular status, drug interactions, seizure/fall risk, liver function and other factors.
When is hormone therapy used?
- Metastatic hormone-sensitive prostate cancer — usually with treatment intensification rather than ADT alone.
- Metastatic or non-metastatic castration-resistant prostate cancer as part of ongoing systemic therapy.
- With radiation for selected unfavourable intermediate-, high- or very-high-risk localized/locally advanced disease.
- Salvage radiation after prostatectomy in selected higher-risk recurrence.
- Symptom control or disease control when local curative treatment is not appropriate.
How long is ADT given?
Duration depends entirely on the indication. When combined with radiation for localized disease, ADT may be prescribed for months to years depending on risk. In metastatic disease, testosterone suppression is usually continuous even when other drugs are changed. Do not stop injections or tablets simply because PSA has fallen unless your oncology team has planned an intermittent strategy in a specific setting.
What monitoring is needed?
- PSA and, when relevant, serum testosterone to confirm adequate suppression.
- Blood pressure, weight and waist circumference.
- Glucose or HbA1c and lipid profile.
- Bone-health assessment, including DEXA when indicated.
- Blood counts, liver/kidney function or electrolytes depending on additional medicines.
- Assessment of hot flushes, mood, sleep, sexual health, fatigue and physical function.
Can side effects be reduced?
Regular resistance and aerobic exercise is one of the most useful interventions for preserving muscle, physical function and metabolic health. Adequate protein intake, healthy weight, smoking cessation and cardiovascular-risk control are important. Bone health may require calcium/vitamin D optimization and, in higher fracture-risk patients, prescription bone-protective treatment.
Fertility and sexual function
ADT usually reduces libido, erectile function and sperm production. Men who may want future biological children should discuss fertility preservation before starting long-term treatment. Sexual side effects are medical issues and can be addressed with counselling and erectile-dysfunction treatment where appropriate.
Hormone therapy now has several layers
| Treatment layer | Examples | Role |
|---|---|---|
| Androgen deprivation | LHRH/GnRH agonist, GnRH antagonist, or orchiectomy | Lowers testicular testosterone and forms the backbone of systemic treatment. |
| Androgen-receptor pathway inhibition | Abiraterone, enzalutamide, apalutamide, darolutamide and related agents | Blocks androgen production or signalling more completely and improves outcomes in several disease settings. |
| Chemotherapy added to hormonal treatment | Docetaxel in selected metastatic patients | May be used as part of triplet therapy in fit men with appropriate disease characteristics. |
Because these drugs work at different points in the androgen pathway, “hormone therapy” no longer means one injection given in the same way to everyone. The combination and duration depend on whether disease is localized with radiation, metastatic hormone-sensitive, non-metastatic castration-resistant or metastatic castration-resistant.
Why testosterone is checked when the cancer appears to progress
Castration-resistant prostate cancer is defined by progression despite testosterone being in the castrate range. If PSA rises or scans worsen while a patient is receiving ADT, checking testosterone helps confirm that the hormonal suppression is actually adequate before the disease is labelled resistant. Treatment is then changed according to previous therapies, symptoms, sites of spread, molecular findings and fitness.
The duration of ADT depends on why it is being given
ADT used with radiotherapy for localized or locally advanced disease is often time-limited, with the duration chosen according to the cancer risk group and radiation plan. ADT for metastatic disease is generally continuous, although the accompanying systemic medicines may change over time. A patient should therefore know whether the current plan is a finite course or long-term suppression.
This distinction matters for fertility, sexual function, bone health and expectations about testosterone recovery. After a finite course, testosterone can take months to recover and may remain low for longer after prolonged treatment, especially in older men.
Drug choice should reflect medical history
Androgen-pathway drugs do not have identical side-effect profiles. Hypertension, heart failure, diabetes, liver disease, falls risk, seizure history, interacting medicines and the need for steroids can all influence which agent is safer. A treatment that is excellent for one patient may be a poor fit for another even when the cancer stage is the same.
When to seek urgent medical care
During hormone therapy, urgent assessment is needed for chest pain, severe breathlessness, fainting, a painful swollen leg, new focal weakness or confusion, or severe back pain with leg weakness/numbness or loss of bladder/bowel control. Do not wait for the next routine oncology visit if these symptoms occur.
Consultation checklist
- Cancer stage and current PSA.
- Previous prostate-cancer treatments.
- Current testosterone if already on ADT.
- Blood pressure, diabetes/HbA1c and lipid history.
- Bone-density or fracture history.
- Cardiovascular history and current medicines.
- Full medication list for drug-interaction review.
FAQs
Is hormone therapy chemotherapy?
No. ADT and androgen-receptor pathway medicines act on hormonal signalling. Chemotherapy works through different mechanisms and may be combined with hormonal treatment in selected metastatic disease.
Will PSA always become zero on ADT?
Not necessarily. A strong PSA fall is common, but the depth and speed of response vary. PSA is interpreted with symptoms, imaging and testosterone.
Can ADT be stopped when PSA is low?
Only if your treatment plan specifically allows it. In metastatic disease, testosterone suppression is usually continued even when other drugs are added or changed.
Does ADT cause osteoporosis?
Long-term testosterone suppression accelerates bone loss and fracture risk. Exercise, nutrition, DEXA assessment and bone-protective medication in selected patients are important.
Can ADT increase diabetes or heart risk?
It can worsen body composition, insulin resistance and cardiovascular risk factors. Baseline risk assessment and ongoing monitoring are part of good cancer care.
Why am I receiving both an injection and tablets?
They often block the androgen pathway at different levels. In several prostate-cancer settings, combination therapy controls cancer better than ADT alone, but it also requires additional side-effect monitoring.
Related reading
- ADT Side Effects in Prostate Cancer
- Metastatic Prostate Cancer Explained
- Radiation vs Surgery for Prostate Cancer
- PSA After Prostate Cancer Treatment
- Prostate Cancer Recurrence Explained
- Targeted Therapy for Kidney Cancer
- Urologist in Latur
References
- European Association of Urology (EAU). EAU Guidelines on Prostate Cancer. 2026 edition https://uroweb.org/guidelines/prostate-cancer
- National Cancer Institute. Prostate Cancer Treatment (PDQ®)–Patient Version https://www.cancer.gov/types/prostate/patient/prostate-treatment-pdq
- American Urological Association/SUO. Advanced Prostate Cancer Guideline (2020; amended 2026) https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer